I'd like to start by thanking our authors and experts for their time and anticipated contributions to our discussion over the next several days.
It is a pleasure to be part of the discussion on this remarkable publication. The collaborative effort among these authors has led to the identification of a biomarker, CDX2, which can be used to stratify patients with stage II colon cancer into a subgroup that is likely to benefit from adjuvant chemotherapy (rather than surgery alone).
In case you haven't been active in one of these discussions previously, we welcome questions that can be directed toward a specific individual as well as broader questions for any of the authors or experts to reply. Over the next several days, I will be posting at least one new question daily and look forward to an active discussion.
If there any questions from the community, please feel free to post them at any time!